---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-127337"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-12-15T23:59:59+00:00"
generated_at: "2026-06-21T04:14:42.248542+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA appoints Katia Schlienger as CMO and Malte Peters to board effective Jan 1, 2023

## Summary
- Katia Schlienger promoted to CMO effective Jan 1, 2023; previously EVP Clinical R&D since July 2022.
- Malte Peters appointed to Board of Directors effective Jan 1, 2023; retiring as MorphoSys Chief R&D Officer at end of 2022.
- Schlienger spent 14 years at Merck & Co. in oncology and vaccine development.
- Peters previously held leadership roles at Novartis Oncology, Sandoz, and Micromet; also on Tango Therapeutics board.
- Peters receives initial option for 19,200 shares, $40k annual cash retainer, and stock awards per non-employee director policy.

## SEC filing metadata
- accession: 0001104659-22-127337
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465922127337/0001104659-22-127337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465922127337/tm2232803d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-127337
- JSON: https://secwatch.observer/filing/0001104659-22-127337.json
- Plain text: https://secwatch.observer/filing/0001104659-22-127337.txt

## Key facts
- Executive change
  Malte Peters was appointed as Director at HOOKIPA Pharma Inc..
  - Action: appointed
  - Role: Director
  source text: On December 9, 2022, the Board of Directors (the “Board”) of HOOKIPA Pharma Inc. (the Company”) appointed Malte Peters, M.D. as a director of the Board, effective January 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000110465922127337/0001104659-22-127337-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.